Empagliflozin Reduced Mortality and Hospitalization for Heart Failure across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

Circulation

Volumn 139, Issue 11, 2019, Pages 1384-1395

  Fitchett, David ^a   Inzucchi, Silvio E ^b   Cannon, Christopher P ^c   McGuire, Darren K ^d   Scirica, Benjamin M ^c   Johansen, Odd Erik ^e   Sambevski, Steven ^f   Kaspers, Stefan ^f   Pfarr, Egon ^f   George, Jyothis T ^f   Zinman, Bernard ^g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e Boehringer Ingelheim Norway KS   (Norway)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cardiovascular diseases; Carotid artery diseases; Death, sudden, cardiac; Diabetes mellitus, type 2; Sodium glucose transporter 2

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EMPAGLIFLOZIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MINERALOCORTICOID ANTAGONIST; PLACEBO; SULFONYLUREA; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ALL CAUSE MORTALITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SECONDARY PREVENTION; ADVERSE EVENT; AGED; ATHEROSCLEROSIS; BLOOD; CAUSE OF DEATH; HOSPITAL ADMISSION; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; ATHEROSCLEROSIS; BENZHYDRYL COMPOUNDS; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PATIENT ADMISSION; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85062326907     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.118.037778     Document Type: Article

References (46)

1. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W, The cardiovascular disease continuum validated: Clinical evidence of improved patient outcomes: Part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006 114 2850 2870. doi: 10.1161/CIRCULATIONAHA.106.655688
2. Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Röther J, Salette G, Goto S, Smith SC Jr, Liau CS, Wilson PW, Steg PG, REduction of Atherothrombosis for Continued Health Registry Investigators Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009 30 2318 2326. doi: 10.1093/eurheartj/ehp355
3. Khan H, Kalogeropoulos AP, Zannad F, Marti CN, Wilson PW, Georgiopoulou VV, Kanaya AM, Newman AB, Schelbert E, Harris TB, Kritchevsky S, Yancy C, Gheorghiade M, Fonarow GC, Butler J, Health ABC Study Incident heart failure in relation to vascular disease: Insights from the Health, Aging, and Body Composition Study. Eur J Heart Fail 2014 16 526 534. doi: 10.1002/ejhf.69
4. Lehrke M, Marx N, Diabetes mellitus and heart failure. Am J Med 2017 130 6S S40 S50. doi: 10.1016/j.amjmed.2017.04.010
5. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010 375 2215 2222
6. van der Heijden AA, Van't Riet E, Bot SD, Cannegieter SC, Stehouwer CD, Baan CA, Dekker JM, Nijpels G, Risk of a recurrent cardiovascular event in individuals with type 2 diabetes or intermediate hyperglycemia: The Hoorn Study. Diabetes Care 2013 36 3498 3502. doi: 10.2337/dc12-2691
7. Bergmark BA, Bhatt DL, Braunwald E, Morrow DA, Steg PG, Gurmu Y, Cahn A, Mosenzon O, Raz I, Bohula E, Scirica BM, Risk assessment in patients with diabetes with the TIMI risk score for atherothrombotic disease. Diabetes Care 2018 41 577 585. doi: 10.2337/dc17-1736
8. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study (UKPDS) Group The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001 101 671 679. doi: 10.1042/cs1010671
9. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB, Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 1837 1847. doi: 10.1161/01.CIR.97.18.1837
10. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E, The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000 284 835 842. doi: 10.1001/jama.284.7.835
11. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD, Fox KA, GRACE Investigators A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004 291 2727 2733. doi: 10.1001/jama.291.22.2727
12. Wilson PW, D'Agostino R Sr, Bhatt DL, Eagle K, Pencina MJ, Smith SC, Alberts MJ, Dallongeville J, Goto S, Hirsch AT, Liau CS, Ohman EM, Röther J, Reid C, Mas JL, Steg PG, REACH Registry An international model to predict recurrent cardiovascular disease. Am J Med 2012 125 695 703.e1. doi: 10.1016/j.amjmed.2012.01.014
13. Bohula EA, Bonaca MP, Braunwald E, Aylward PE, Corbalan R, De Ferrari GM, He P, Lewis BS, Merlini PA, Murphy SA, Sabatine MS, Scirica BM, Morrow DA, Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction. Circulation 2016 134 304 313. doi: 10.1161/CIRCULATIONAHA.115.019861
14. Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E, Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol 2017 69 911 921. doi: 10.1016/j.jacc.2016.11.070
15. Bohula EA, Morrow DA, Pedersen TR, Kanevsky E, Murphy SA, Giugliano RP, Sever PS, Keech AC, Sabatine MS, Atherothrombotic risk stratification and magnitude of benefit of evolocumab in FOURIER. Circulation 2017 136 A20183
16. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Mas JL, Richard AJ, Röther J, Wilson PW, REACH Registry Investigators The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006 151 786.e1 786.10. doi: 10.1016/j.ahj.2005.11.004
17. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720
18. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, D'Agostino R, Liau CS, Mas JL, Röther J, Smith SC Jr, Salette G, Contant CF, Massaro JM, Steg PG, REACH Registry Investigators Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010 304 1350 1357. doi: 10.1001/jama.2010.1322
19. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL, REACH Registry Investigators Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: Outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 2015 132 923 931. doi: 10.1161/CIRCULATIONAHA.114.014796
20. Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Alegiani SS, Raschetti R, Velussi M, Ferrannini E, Diabetes and Informatics Study Group Recurrence of cardiovascular events in patients with type 2 diabetes: Epidemiology and risk factors. Diabetes Care 2008 31 2154 2159. doi: 10.2337/dc08-1013
21. Mehta S, Ghosh S, Sander S, Kuti E, Mountford WK, Differences in all-cause health care utilization and costs in a type 2 diabetes mellitus population with and without a history of cardiovascular disease. J Manag Care Spec Pharm 2018 24 280 290. doi: 10.18553/jmcp.2018.24.3.280
22. Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, Amarenco P, LaRosa JC, Cramer MJ, Westerink J, Kappelle LJ, de Borst GJ, Visseren FL, Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation 2016 134 1419 1429. doi: 10.1161/CIRCULATIONAHA.116.021314
23. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M, Excess mortality among persons with type 2 diabetes. N Engl J Med 2015 373 1720 1732. doi: 10.1056/NEJMoa1504347
24. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017 377 644 657. doi: 10.1056/NEJMoa1611925
25. Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B, Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: Subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia 2018 61 1712 1723. doi: 10.1007/s00125-018-4644-9
26. Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, George JT, Zinman B, Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: A subanalysis of EMPA-REG OUTCOME. Circulation 2018 137 405 407. doi: 10.1161/CIRCULATIONAHA.117.032031
27. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME® trial investigators Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016 37 1526 1534. doi: 10.1093/eurheartj/ehv728
28. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, Satterfield S, Smith AL, Vaccarino V, Newman AB, Harris TB, Wilson PW, Kritchevsky SB, Health ABC Study Incident heart failure prediction in the elderly: The health ABC heart failure score. Circ Heart Fail 2008 1 125 133. doi: 10.1161/CIRCHEARTFAILURE.108.768457
29. Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE, EMPA-REG OUTCOME® trial investigators Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J 2018 39 363 370. doi: 10.1093/eurheartj/ehx511
30. Ridderstråle M, Toural E, Fitchett D, Giljanovic Kîs S, Woerle HJ, Mattheus M, Zinman B, Inzucchi SE, Effect of empagliflozin on cardiovascular death in subgroups by age: Results from EMPA-REG OUTCOME. Diabetes 2016 65 A289. [1109-P]
31. Monteiro P, Schaper N, Clark D, Hantel S, Woerle HJ, Inzucchi SE, Fitchett D, Effect of empagliflozin on heart failure outcomes in subgroups by age: Results from EMPA-REG OUTCOME. Diabetes 2016 65 A291. [1116-P]
32. Zinman B, Inzucchi SE, Wanner C, Hehnke U, George JT, Johansen OE, Fitchett D, EMPA-REG OUTCOME® investigators Empagliflozin in women with type 2 diabetes and cardiovascular disease-an analysis of EMPA-REG OUTCOME®. Diabetologia 2018 61 1522 1527. doi: 10.1007/s00125-018-4630-2
33. Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Woerle HJ, Zinman B, Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: Results from the EMPA-REG OUTCOME trial. Eur J Heart Fail 2017 19 suppl P490
34. Inzucchi SE, Fitchett D, Wanner C, Mattheus M, George JT, Woerle HJ, Zinman B, Reduction in cardiovascular (CV) death with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: Results from the EMPA-REG OUTCOME trial. Diabetes 2017 66 suppl 1 A313. [1174-P]
35. Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B, EMPA-REG OUTCOME Investigators Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 2018 137 119 129. doi: 10.1161/CIRCULATIONAHA.117.028268
36. George JT, Fitchett D, Lachin J, Wanner C, Pfarr E, Zinman B, EMPA-REG OUTCOME: Empagliflozin reduced the risk of cardiovascular outcomes irrespective of smoking status. Paper presented at: IDF Congress 2017 Abu Dhabi
37. Fitchett D, McKnight J, Lee J, George JT, Mattheus M, Woerle HJ, Inzucchi SE, Empagliflozin (EMPA) reduces heart failure irrespective of control of blood pressure (BP), low density lipoprotein cholesterol (LDL-C) and HbA1c. Diabetes 2017 66 suppl 1 A312 A313. [1172-P]
38. Zinman B, Mathieu C, Kaspers S, Mattheus M, Woerle HJ, Fitchett D, Empagliflozin (EMPA) reduces mortality in analyses adjusted for control of blood pressure (BP), low density lipoprotein cholesterol (LDL-C) and HbA1c over time. Diabetes 2017 66 suppl 1 A313. [1173-P]
39. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC, Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus. Clin Ther 2016 38 2248 2264.e5. doi: 10.1016/j.clinthera.2016.08.008
40. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC, Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes. Clin Ther 2016 38 2248 2264.e5. doi: 10.1016/j.clinthera.2016.09.001
41. Schou M, Gullestad L, Fitchett D, Zinman B, Inzucchi SE, Hehnke U, Von Eynatten M, George J, Johansen OE, Wanner C, Empagliflozin exerts short-and long-term effects on plasma volume in patients with type 2 diabetes: Insight from EMPA-REG OUTCOME. Circulation 2017 136 suppl 1 A15997
42. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM, How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 2018 41 356 363. doi: 10.2337/dc17-1096
43. Chilton R, Gullestad L, Park S, Inzucchi SE, Hehnke U, Woerle HJ, Johansen OE, Empagliflozin improves cardiovascular (CV) outcomes regardless of improvement in cardiac and vascular hemodynamic markers in type 2 diabetes patients at high CV risk in EMPA-REG OUTCOME. Circulation 2017 136 suppl 1 A16626
44. Mudaliar S, Alloju S, Henry RR, Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 2016 39 1115 1122. doi: 10.2337/dc16-0542
45. Coleman RL, Gray A, Broedl U, Fitchett D, George JT, Woerle HJ, Zinman B, Holman RR, Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors? Diabetic Medicine 2017 34 suppl 1 23
46. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, DECLARE-TIMI 58 Investigators Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019 380 347 357. doi: 10.1056/NEJMoa1812389